antiretroviral drugs in the perinatal period
Download
Skip this Video
Download Presentation
ANTIRETROVIRAL DRUGS IN THE PERINATAL PERIOD

Loading in 2 Seconds...

play fullscreen
1 / 20

ANTIRETROVIRAL DRUGS IN THE PERINATAL PERIOD - PowerPoint PPT Presentation


  • 68 Views
  • Uploaded on

ANTIRETROVIRAL DRUGS IN THE PERINATAL PERIOD. Use of ARV Drugs by HIV-Infected Pregnant Women and Their Infants. Considerations for choice of ARV drugs for pregnant women include: Possible changes in dosing requirements resulting from physiologic changes associated with pregnancy

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' ANTIRETROVIRAL DRUGS IN THE PERINATAL PERIOD' - midori


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
use of arv drugs by hiv infected pregnant women and their infants
Use of ARV Drugs by HIV-Infected Pregnant Women and Their Infants
  • Considerations for choice of ARV drugs for pregnant women include:
    • Possible changes in dosing requirements resulting from physiologic changes associated with pregnancy
    • Potential exacerbation of ARV drug toxicities
    • Pharmacokinetics and toxicity of transplacentally transferred drugs
    • Potential short- and long-term effects of ARV drugs on fetuses and newborns

www.aidsetc.org

combination art and pregnancy outcome
Combination ART and Pregnancy Outcome
  • Possible small increased risk of preterm birth in pregnant women receiving protease inhibitor (PI)-based ART; however, given the clear benefits, PIs should not be withheld for fear of altering pregnancy outcome. (AII)

www.aidsetc.org

pharmacokinetic changes
Pharmacokinetic Changes
  • Altered dosing during pregnancy may be required for some PIs, such as lopinavir/ritonavir. (AII)
    • Concentrations of the following drugs are reduced during the 2nd and/or 3rd trimesters
      • Lopinavir/ritonavir (LPV/r)
      • Atazanavir (ATV)
      • Darunavir (DRV)
      • Nelfinavir (NFV)
    • The need for dosage adjustment depends on the patient’s treatment experience and use of concomitant medications.

www.aidsetc.org

teratogenicity
Teratogenicity
  • Women of childbearing potential should undergo pregnancy testing before initiating efavirenz(EFV) and receive counseling about the potential risk to the fetus and desirability of avoiding pregnancy while on EFV. (AIII)
  • Consider non-EFV regimens in patients who are: (BIII)
    • Planning to become pregnant
    • Sexually active and not using effective contraception

www.aidsetc.org

slide6

Report all cases of ARV use in pregnant women to the Antiretroviral Pregnancy Registry: http://www.APRegistry.com(AIII)

The registry collects observational, nonexperimental data regarding ARV exposure during pregnancy to assess potential teratogenicity.

www.aidsetc.org

August 2012

nevirapine and hepatic rash toxicity
Nevirapine and Hepatic/Rash Toxicity
  • Avoid initiating NVP in women with CD4 counts >250 cells/µL unless the benefits outweigh the risks. (AII)
    • Risk of hepatotoxicity/hypersensitivity reaction
  • Women who are tolerating NVP-containing regimens and become pregnant can continue regardless of CD4 count. (AII)

www.aidsetc.org

nrti drugs and mitochondrial toxicity
NRTI Drugs and Mitochondrial Toxicity
  • The combination of stavudine (d4T) and didanosine (ddl) should not be prescribed during pregnancy because of reports of lactic acidosis and maternal/neonatal mortality with prolonged use during pregnancy. (AII)
  • Mitochondrial dysfunction should be considered in uninfected children with perinatal exposure to ARV drugs who present with severe clinical findings, particularly neurologic. (AII)
  • Long-term clinical follow-up is recommended for any child with in utero exposure to ARV drugs. (AIII)

www.aidsetc.org

protease inhibitors and hyperglycemia
Protease Inhibitors and Hyperglycemia
  • HIV-infected women taking ARV regimens during pregnancy should undergo standard glucose screening at 24-28 weeks’ gestation. (AIII)
  • Owing to linkage with hyperglycemia:
    • Consider earlier glucose screening in women receiving PI-based regimens initiated before pregnancy. (BIII)

www.aidsetc.org

protease inhibitors 1
Protease Inhibitors (1)

Class concerns for PIs: hyperglycemia, diabetes, question of increased risk of preterm delivery

www.aidsetc.org

additional recommendations by class
Additional Recommendations by Class

Integrase Inhibitors

Entry Inhibitors

www.aidsetc.org

ad